Quince Therapeutics is a clinical-stage biotechnology company that developed the AIDE platform — a drug delivery technology that encapsulates drugs into a patient's own red blood cells at the point of care. Quince's sole product candidate was eDSP, dexamethasone sodium phosphate encapsulated via AIDE, which was being developed for ataxia-telangiectasia (A-T), a rare pediatric neurodegenerative disease with no approved treatments. The clinical rationale was that red blood cell encapsulation could deliver a corticosteroid's anti-inflammatory benefits while avoiding the severe toxicities associated with chronic corticosteroid use. In January 2026, Quince's pivotal Phase 3 NEAT trial failed to meet its primary or key secondary endpoints, leaving the company with no active product candidates and no ongoing development activities. Quince is now effectively a shell company, with its primary asset being its public listing. The company has engaged LifeSci Capital to evaluate strategic alternatives, with a reverse merger as the primary path forward — a common outcome for failed clinical-stage biotechs whose public listings retain value as vehicles for private companies seeking market access. Quince is preserving cash while pursuing a merger partner and may raise additional funds through at-the-market equity offerings or private financing to fund the process.